Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement.
The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika launches late-stage supplemental Cingal study appeared first on MassDevice.
from MassDevice http://ift.tt/2roV51B
Cap comentari:
Publica un comentari a l'entrada